Eli Lilly and Co at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Great. Good morning, everybody. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs, and we're very pleased to be hosting Eli Lilly today at our virtual healthcare conference.
Joining us today from the company, we have Anne White, who is President of Lilly Oncology; and Jake Van Naarden, who is CEO of Loxo Oncology at Lilly. Thank you both so much for joining us today. Really appreciate the time.
Questions & Answers
As I know it's an extremely busy time of the year. You're post the ASCO Conference. Maybe to start, I thought a good place would be just to give us an overview of kind of the company's current strategy here in oncology.
What's differentiated about your approach versus other players? And then how are you thinking about the different verticals, targeted oncology versus IO, as obviously there's a lot of ongoing efforts there at the company.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
